Latest & greatest articles for sitagliptin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sitagliptin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sitagliptin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sitagliptin

21. Sitagliptin/metformin - Benefit assessment according to §35a Social Code Book V

Sitagliptin/metformin - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sitagliptin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 30 September 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A16-45 Sitagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A16-45 Version 1.0 Sitagliptin/metformin (type 2 diabetes mellitus) 30 September 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sitagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

22. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes Full Text available with Trip Pro

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes To assess the safety and efficacy of omarigliptin in Japanese patients with type 2 diabetes (T2D).In a 24-week double-blind trial, 414 patients with T2D were randomized to omarigliptin 25 mg once weekly, sitagliptin 50 mg once daily or placebo. The double-blind period was followed by a 28-week open-label (...) extension during which all patients received omarigliptin 25 mg once weekly. Efficacy endpoints were glycated haemoglobin (HbA1c), 2-hour postprandial glucose (PPG) and fasting plasma glucose (FPG) levels.After 24 weeks, the least squares (LS) mean change from baseline in HbA1c was -0.66% for omarigliptin, -0.65% for sitagliptin and 0.13% for placebo. The difference in LS mean for omarigliptin vs placebo was -0.80% ( P  < .001). The difference in LS mean for omarigliptin vs sitagliptin was -0.02% (95

2017 EvidenceUpdates

23. Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin Full Text available with Trip Pro

Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin Patients with diabetes often have comorbidities such as hypertension. It is not known how individual characteristics influence response to dipeptidyl peptidase-4 (DPP4) inhibitors.We tested the hypothesis that individual characteristics, sitagliptin dose, and genetic variability in DPP4 influence DPP4 activity during sitagliptin.Post hoc analysis of clinical and laboratory data (...) from individuals randomized to sitagliptin versus placebo in crossover studies.Sixty-five subjects [27 with type 2 diabetes mellitus (T2DM) and hypertension, 38 healthy controls] were randomized to 100 mg/d sitagliptin or 200 mg sitagliptin and matching placebo in double-blind, crossover fashion. Fasting blood was obtained at baseline and 60 to 180 minutes after sitagliptin or placebo.DPP4 activity and antigen during placebo and sitagliptin and DPP4 inhibition during sitagliptin.Sitagliptin 100 mg

2017 Journal of the Endocrine Society Controlled trial quality: uncertain

24. [Sitagliptin/metformin - benefit assessment according to õ35a Social Code Book V]

[Sitagliptin/metformin - benefit assessment according to õ35a Social Code Book V] Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-45 [Sitagliptin/metformin - benefit assessment according to §35a Social Code Book V] Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-45 [Sitagliptin/metformin - benefit assessment according to §35a (...) Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sitagliptin/Metformin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag

2017 Health Technology Assessment (HTA) Database.

25. [Sitagliptin - benefit assessment according to õ35a Social Code Book V]

[Sitagliptin - benefit assessment according to õ35a Social Code Book V] Sitagliptin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-44 [Sitagliptin - benefit assessment according to §35a Social Code Book V] Sitagliptin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-44 [Sitagliptin - benefit assessment according to §35a Social Code Book V] Institut für Qualität und (...) Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sitagliptin (Diabetes mellitus Typ 2): nutzenbewertung gemäß § 35a SGB V (ablauf befristung); dossierbewertung; auftrag A16-44. [Sitagliptin - benefit assessment according to §35a Social

2017 Health Technology Assessment (HTA) Database.

26. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial Full Text available with Trip Pro

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial To examine fracture incidence among participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).We used data from 14 671 participants in the TECOS study who were randomized double-blind to sitagliptin (n = 7332) or placebo (n = 7339). Cumulative fracture incidence rates were calculated and their association with study treatment assignment was examined using multivariable Cox proportional (...) increased independently with older age (P < .001), female sex (P < .001), white race (P < .001), lower diastolic blood pressure (P < .001) and diabetic neuropathy (P = .003). Sitagliptin, compared with placebo, was not associated with a higher fracture risk [189 vs 186 incident fractures: unadjusted hazard ratio (HR) 1.01, 95% confidence interval (CI) 0.82 to 1.23, P = .944; adjusted HR 1.03, P = .745], major osteoporotic fractures (P = .673) or hip fractures (P = .761). Insulin therapy was associated

2016 EvidenceUpdates

27. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial Full Text available with Trip Pro

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin.A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes (...) who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch to liraglutide (n = 203) or continue sitagliptin (n = 204), both with metformin. The primary endpoint was change in HbA1c from baseline to week 26. Change in body weight was a confirmatory secondary endpoint.Greater reduction in mean HbA1c was achieved with liraglutide than with continued sitagliptin [-1.14% vs. -0.54

2016 EvidenceUpdates Controlled trial quality: predicted high

28. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial Full Text available with Trip Pro

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial To investigate effects of dipeptidyl peptidase-4 inhibitor (DPP-4I) sitagliptin or glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide treatment on renal hemodynamics, tubular functions, and markers of renal damage in overweight patients with type 2 diabetes without chronic kidney disease (CKD (...) ).In this 12-week, randomized, double-blind trial, 55 insulin-naïve patients with type 2 diabetes (mean ± SEM: age 63 ± 7 years, BMI 31.8 ± 4.1 kg/m2, glomerular filtration rate [GFR] 83 ± 16 mL/min/1.73 m2; median [interquartile range]: albumin-to-creatinine ratio (ACR) 1.09 mg/mmol [0.47-3.31]) received sitagliptin (100 mg/day), liraglutide (1.8 mg/day), or matching placebos. GFR (primary end point) and effective renal plasma flow (ERPF) were determined by inulin and para-aminohippuric acid clearance

2016 EvidenceUpdates Controlled trial quality: predicted high

29. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. Full Text available with Trip Pro

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and secondary composite atherosclerotic cardiovascular (CV) outcomes (...) in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).To assess the association of sitagliptin use with hospitalization for HF (hHF) and related outcomes.TECOS was a randomized, double-blind, placebo-controlled study evaluating the CV safety of sitagliptin vs placebo, each added to usual antihyperglycemic therapy and CV care among patients with T2DM and prevalent atherosclerotic vascular disease. The median follow-up was 2.9 years. The setting was 673 sites in 38 countries. Participants

2016 JAMA cardiology Controlled trial quality: predicted high

30. JANUVIA 50 mg and XELEVIA 50 mg (sitagliptin), DPP-4 inhibitor

JANUVIA 50 mg and XELEVIA 50 mg (sitagliptin), DPP-4 inhibitor JANUVIA XELEVIA SUMMARY CT12571 CT12572

2016 Haute Autorite de sante

31. Dynamic Change of Focal Fatty Sparing in Non-Alcoholic Fatty Liver Disease after Treatment with Sitagliptin Full Text available with Trip Pro

Dynamic Change of Focal Fatty Sparing in Non-Alcoholic Fatty Liver Disease after Treatment with Sitagliptin 27689184 2016 10 05 2019 02 26 2509-596X 2 3 2016 Sep Ultrasound international open Ultrasound Int Open Dynamic Change of Focal Fatty Sparing in Non-Alcoholic Fatty Liver Disease after Treatment with Sitagliptin. E98-9 10.1055/s-0036-1582302 Hoffmanová I I Škrha P P Šedo A A Anděl M M eng Case Reports 2016 06 07 Germany Ultrasound Int Open 101674542 2199-7152 2016 10 1 6 0 2016 10 1 6 0

2016 Ultrasound international open

32. Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin Full Text available with Trip Pro

Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin.In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg (...) with placebo (p < 0.001). The overall AE incidence was 39.8 and 44.4% for canagliflozin and placebo, respectively. Canagliflozin was associated with an increased incidence of genital mycotic infections.Titrated canagliflozin significantly improved HbA1c, FPG, body weight and SBP, and was generally well tolerated over 26 weeks in patients with T2DM as add-on to metformin and sitagliptin.© 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2016 EvidenceUpdates Controlled trial quality: uncertain

33. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial Full Text available with Trip Pro

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial To compare the efficacy and safety of liraglutide versus sitagliptin as add-on to metformin after 26 weeks of treatment in Chinese patients with type 2 diabetes mellitus (T2DM).This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM (...) inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily oral sitagliptin 100 mg (n = 184), both as add-on to metformin. The primary endpoint was change in HbA1c from baseline to week 26.Liraglutide was superior to sitagliptin in reducing HbA1c from baseline [8.1% (65 mmol/mol)] to 26 weeks, as evidenced by estimated mean HbA1c change of -1.65% (-18.07 mmol/mol) versus -0.98

2016 EvidenceUpdates Controlled trial quality: uncertain

34. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. Full Text available with Trip Pro

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.To examine the associations of hHF with saxagliptin and sitagliptin.Population-based, retrospective, new-user (...) cohort study.18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded

2016 Annals of Internal Medicine

35. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. (Abstract)

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 26672857 2015 12 18 2018 12 02 1533-4406 373 25 2015 12 17 The New England journal of medicine N. Engl. J. Med. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 2479 10.1056/NEJMc1510995 Holman Rury R RR Peterson Eric D ED eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Pyrazines 0 Triazoles AIM IM N Engl J Med. 2015 Jul 16;373(3):232-42 26052984 N Engl J Med. 2015 Dec 17;373(25):2478

2015 NEJM

36. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. Full Text available with Trip Pro

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 26672858 2015 12 18 2018 12 02 1533-4406 373 25 2015 12 17 The New England journal of medicine N. Engl. J. Med. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 2478 10.1056/NEJMc1510995 Rutter Martin K MK Wright Alison K AK Ashcroft Darren M DM eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Pyrazines 0 Triazoles AIM IM N Engl J Med. 2015 Jul 16;373(3):232-42 26052984 N Engl J Med

2015 NEJM

37. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. Full Text available with Trip Pro

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 26672859 2015 12 18 2018 12 02 1533-4406 373 25 2015 12 17 The New England journal of medicine N. Engl. J. Med. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 2478 10.1056/NEJMc1510995 Kumar Hari K V S HK eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Pyrazines 0 Triazoles AIM IM N Engl J Med. 2015 Jul 16;373(3):232-42 26052984 N Engl J Med. 2015 Dec 17;373(25):2479 26672857

2015 NEJM

38. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. Full Text available with Trip Pro

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 26672860 2015 12 18 2018 12 02 1533-4406 373 25 2015 12 17 The New England journal of medicine N. Engl. J. Med. Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. 2479 10.1056/NEJMc1510995 Kay G Neal GN eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Pyrazines 0 Triazoles AIM IM N Engl J Med. 2015 Jul 16;373(3):232-42 26052984 N Engl J Med. 2015 Dec 17;373(25):2479 26672857

2015 NEJM

39. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Full Text available with Trip Pro

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | NEJM logo-32 logo-40 logo-60 Follow Us Stay connected to what's important in medical research and clinical practice Subscribe to the most trusted and influential source of medical knowledge Already a subscriber? or Search site Keyword Specialties Selected specialties Topics Selected Topics Multimedia Selected Multimedia Current Issue Current Issue Recent (...) Issues Recently Published Articles Learning/CME Other NEJM Group Learning Keyword Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes Article Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes ( ). In Table 1, in the “Intention-to-treat analysis” portion of the table (page 239), the value given for Acute pancreatitis in the “no. per 100 person-yr” column under “Placebo” should have been 0.06, rather than 0.11. The article is correct at NEJM.org. Citing Articles (4

2015 NEJM

40. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Full Text available with Trip Pro

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching (...) individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina.During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29

2015 NEJM Controlled trial quality: predicted high